Accessibility Menu
IR-Med logo

IR-Med(OTC) IRME

Market Cap$204.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)-100%
5 Year-100%
1 Year-88%
1 Month-70%
$0.00
+0.00%
+0.00Today
IR-Med last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-11
IR-Med stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-24
1 month-70%USD 0.012026-05-26
3 month-70%USD 0.012026-04-30
Year to date-93%USD 0.032025-12-30
1 year-88.2%USD 0.022025-08-11
3 year-99.79%USD 1.002023-08-10
5 year-99.93%USD 3.022021-08-12
Since inception-100%USD 3,205,128.212009-05-18

IR-Med Financials at a Glance

Market Cap

$204.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$26.00K

Net Income (TTM)

-$2.35M

EPS (TTM)

-$0.03

P/E Ratio

-0.06

Dividend

$0.00

Beta (Volatility)

-0.32 (Low)

Price

$0.00

Volume

1

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.05

Estimated Earnings Date

Sep 2, 2026

IRME News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About IR-Med

IR-Med Inc. is an emerging medical technology firm focused on developing advanced diagnostic and medical solutions. The company leverages a platform that integrates infrared light spectroscopy with artificial intelligence to create innovative healthcare products.

Products and Services
  • PressureSafe: A handheld device for early detection of pressure-induced tissue damage
  • Nobiotics: An otoscope providing immediate feedback on middle ear infections
  • Advanced diagnostic solutions utilizing AI and infrared technology
Growth Outlook
  • Strong potential in the medical device market, projected to grow significantly
  • Innovative product pipeline addressing critical healthcare needs
  • Strategic focus on expanding market presence and partnerships
Financial Highlights
  • Recent quarterly net income of -$701,000, reflecting ongoing investment in R&D
  • Trailing twelve months (TTM) revenue of $0, indicating early-stage development
  • Cash and cash equivalents increased to $63,000 in Q2 2025
IR-Med Inc. operates in the healthcare sector, specifically within medical devices, and is headquartered in Rosh Pina, Israel. The company is dedicated to addressing significant healthcare challenges through its innovative products. The PressureSafe device aims to improve patient care by identifying tissue damage early, while Nobiotics targets a common pediatric condition, enhancing diagnostic capabilities for healthcare professionals. The growth outlook for IR-Med is promising, with the medical device market expected to expand significantly in the coming years. The company's focus on developing advanced diagnostic solutions positions it well to capitalize on this growth. Additionally, the strategic emphasis on partnerships and market expansion may further enhance its competitive edge. Financially, IR-Med is in the early stages of its development, as indicated by the recent quarterly net income and TTM revenue figures. The company is investing heavily in research and development, which is reflected in its operating expenses. Despite the current financial challenges, the increase in cash reserves suggests a commitment to sustaining operations and pursuing growth opportunities. Overall, IR-Med Inc. presents a unique investment opportunity in the medical technology space, with innovative products and a strategic growth plan aimed at addressing critical healthcare needs.
AI Generated • Aug 1, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

4

CEO

Ran Ziskind

Website

www.ir-medical.com

Headquarters

Rosh Pinna, HZ 1231400, IL

IRME Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

263.69%

Return on Capital

N/A

Return on Assets

-842.29%

Earnings Yield

-16.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$204.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

97.38M

Volume

1

Avg. Volume

96.857

Financials (TTM)

Gross Profit

$2.00K

Operating Income

-$1.46M

EBITDA

-$1.40M

Operating Cash Flow

-$837.00K

Capital Expenditure

$0.00

Free Cash Flow

-$837.00K

Cash & ST Invst.

$63.00K

Total Debt

$250.00K

IR-Med Performance Analysis

IR-Med annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
IR-Med sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-30N/A
Q42024-12-31N/A
Q12025-03-31-100.0%
Q22025-06-30N/A
IR-Med annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.06N/A
20222022-12-31USD -0.0718.8%
20232023-12-31USD -0.071.0%
20242024-12-31USD -0.03-61.8%
IR-Med sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-30-63.5%
Q42024-12-3154.1%
Q12025-03-31-176.9%
Q22025-06-3012.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$4.00K

+0.0%

Gross Margin

0.00%

N/A

Market Cap

$204.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$68.17K

N/A

Employees

3

N/A

Net Income

-$701.00K

-91.5%

EBITDA

-$282.00K

+20.3%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

$63.00K

-91.6%

Total Debt

$250.00K

+59.2%

Accounts Receivable

$27.00K

-25.0%

Inventory

$0.00

N/A

Long Term Debt

$26.00K

-83.4%

Short Term Debt

$224.00K

N/A

Return on Assets

-8.42%

N/A

Return on Invested Capital

89.98%

N/A

Free Cash Flow

-$71.00K

+80.9%

Operating Cash Flow

-$71.00K

+80.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SIGYSigyn Therapeutics, Inc.
$0.03+0.00%
SLDXStella Diagnostics Inc.
$0.01+0.00%
LMLLFPharmadrug Inc.
$0.01+84.00%
LLBOLifeline Biotechnologies, Inc.
$0.00-33.33%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.61-0.02%
SPCXSpace Exploration Technologies
$146.23+0.04%
IPSTIp Strategy
$7.39+2.36%
NVDANvidia
$225.01-0.00%

Questions About IRME

What is the current price of IR-Med?

IR-Med is trading at $0.00 per share.

What is the 52-week range for IR-Med?

Over the past 52 weeks, IR-Med has traded between $0.00 and $0.05.

How much debt does IR-Med have?

As of the most recent reporting period, IR-Med reported total debt of $250.00K.

How much cash does IR-Med have on hand?

IR-Med reported $63.00K in cash and cash equivalents in its most recent financial results.

What is IR-Med’s dividend yield?

IR-Med does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services